LLY Stock In Spotlight After Wall Street Reaffirms Confidence Post FDA Adverse Event Flag

• According to TheFly, Eli Lilly told Wolfe Research that, in line with its standard procedures, Lilly Global Patient Safety thoroughly assessed the individual report and determined it was not reasonably related to Foundayo.
• Wolfe Research noted that with the additional context from the company, it feels confident that the pre-market trading reaction was “overdone."
• RBC Capital said it believes that the single Foundayo case "represents baseline noise, not a mechanistic safety signal.”

Shares of Eli Lilly and Co. (LLY) traded in the red on Monday morning and pared most of the losses later after the U.S. Food and Drug Administration highlighted through its Adverse Event monitoring system that a 56-year-old male patient had hepatic failure following use of the company’s Foundayo.

According to TheFly, the case was reported to the FDA on April 30. It also reported that Wolfe Research had reached out to Lilly for more details, given the importance of Foundayo's safety profile.

Eli Lilly’s Response To Wolfe Research

Following this, Eli Lilly told Wolfe Research that in line with its standard procedures, Lilly Global Patient Safety thoroughly assessed the individual report, which was submitted within days of commercial availability, and determined it was not reasonably related to Foundayo.

Wolfe Research noted that with the additional context from the company, it feels confident that the pre-market trading reaction was “overdone." Wolfe Research has an ‘Outperform’ rating on the stock with a price target of $1,325.

RBC Capital’s Take

Meanwhile, RBC Capital also highlighted Eli Lilly’s response to the firm and highlighted that the clinical data was “clean." The firm noted that injectable GLP-1s have demonstrated liver issues, and hepatic events are a class-wide phenomenon driven by confounding factors in obese and Type 2 diabetes.

RBC Capital said it believes that the single Foundayo case "represents baseline noise, not a mechanistic safety signal." The firm has an ‘Outperform’ rating on the stock with a price target of $1,250.

What Is Foundayo?

Eli Lilly describes Foundayo as a prescription medicine that is used with a reduced-calorie diet and increased physical activity to help “adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.”

Lilly also highlights that Foundayo should not be used with other GLP-1 receptor agonist medicines.

How Did Retail Traders React?

Retail sentiment on Stocktwits continued to remain in the ‘extremely bullish’ territory with high message volume.

LLY shares have lost over 11% year to date. The Vanguard Total Stock Market Index Fund ETF (VTI) and the Vanguard S&P 500 ETF (VOO) have gained over 5.5% year to date.

For updates and corrections, email newsroom[at]stocktwits[dot]com